Publications

Found 97 results
[ Type(Asc)] Year
Journal Article
T Gaj, CA Gersbach, and CF Barbas. "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering." Trends in Biotechnology 31, no. 7 (2013): 397-405.
JE Phillips, CA Gersbach, and AJ García. "Virus-based gene therapy strategies for bone regeneration." Biomaterials 28, no. 2 (2007): 211-229.
S Chakraborty, H Ji, J Chen, CA Gersbach, and KW Leong. "Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis." Scientific Reports 4 (2014).
JP Tremblay, X Xiao, A Aartsma-Rus, C Barbas, HM Blau, AJ Bogdanove, K Boycott, S Braun, XO Breakefield, JA Bueren et al. "Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases." Molecular Therapy 21, no. 2 (2013): 266-268.
KA Glass, JM Link, JM Brunger, FT Moutos, CA Gersbach, and F Guilak. "Tissue-engineered cartilage with inducible and tunable immunomodulatory properties." Biomaterials 35, no. 22 (2014): 5921-5931.
KA Glass, JM Link, JM Brunger, FT Moutos, CA Gersbach, and F Guilak. "Tissue-engineered cartilage with inducible and tunable immunomodulatory properties." Biomaterials 35, no. 22 (2014): 5921-5931.
CA Gersbach, and CFB III. "Targeted plasmid integration into the Human Genome by engineered recombinases." Topics in Current Genetics 23 (2013): 267-284.
CA Gersbach, T Gaj, RM Gordley, AC Mercer, and CF Barbas. "Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase." Nucleic Acids Research 39, no. 17 (2011): 7868-7878.
JB Black, AF Adler, HG Wang, AM D'Ippolito, HA Hutchinson, TE Reddy, GS Pitt, KW Leong, and CA Gersbach. "Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells." Cell Stem Cell 19, no. 3 (2016): 406-414.
CA Gersbach, T Gaj, and CF Barbas. "Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies." Accounts of Chemical Research 47, no. 8 (2014): 2309-2318.
RM Gordley, CA Gersbach, and CF Barbas. "Synthesis of programmable integrases." Proceedings of the National Academy of Sciences of USA 106, no. 13 (2009): 5053-5058.
P Perez-Pinera, DG Ousterout, JM Brunger, AM Farin, KA Glass, F Guilak, GE Crawford, AJ Hartemink, and CA Gersbach. "Synergistic and tunable human gene activation by combinations of synthetic transcription factors." Nature Methods 10, no. 3 (2013): 239-242.
T Gaj, AC Mercer, CA Gersbach, RM Gordley, and CFB III. "Structure-guided reprogramming of serine recombinase DNA sequence specificity." Proceedings of the National Academy of Sciences of USA 108, no. 2 (2011): 510-515.
T Gaj, AC Mercer, CA Gersbach, RM Gordley, and CF Barbas. "Structure-guided reprogramming of serine recombinase DNA sequence specificity." Proceedings of the National Academy of Sciences of USA 108, no. 2 (2011): 498-503.
EA Josephs, DD Kocak, CJ Fitzgibbon, J McMenemy, CA Gersbach, and PE Marszalek. "Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic Acids Research 43, no. 18 (2015): 8924-8941.
EA Josephs, DD Kocak, CJ Fitzgibbon, J McMenemy, CA Gersbach, and PE Marszalek. "Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic Acids Research 44, no. 5 (2016).
AM Kabadi, and CA Gersbach. "Special issue on engineered DNA-binding proteins." ACS Synthetic Biology 3, no. 10 (2014): 702-703.
J Drevs, U Zirrgiebel, CIM Schmidt-Gersbach, K Mross, M Medinger, L Lee, J Pinheiro, J Wood, AL Thomas, C Unger et al. "Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials." Annals of Oncology 16, no. 4 (2005): 558-565.
TM Gibson, and CA Gersbach. "Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment." Integrative Biology 7, no. 6 (2015): 663-671.
JM Brunger, NP Huynh, CM Guenther, P Perez-Pinera, FT Moutos, J Sanchez-Adams, CA Gersbach, and F Guilak. "Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage." Proceedings of the National Academy of Sciences of USA 111, no. 9 (2014): E798-E806.
CA Gersbach, BA Byers, RE Guldberg, GK Pavlath, and AJ García. "Runx2-stimulated transdifferentiation of primary skeletal myoblasts into an osteoblastic mineralizing phenotype for bone tissue engineering." Transactions - 7th World Biomaterials Congress (2004).
CA Gersbach, JE Phillips, RE Guldberg, and AJ García. "Runx2-genetically engineered cells for bone tissue engineering." Proceedings of the 2005 Summer Bioengineering Conference 2005 (2005): 603-604.
CA Gersbach, BA Byers, GK Pavlath, RE Guldberg, and AJ García. "Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro." Biotechnology & Bioengineering 88, no. 3 (2004): 369-378.
CA Gersbach, BA Byers, GK Pavlath, and AJ García. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Experimental Cell Research 300, no. 2 (2004): 406-417.
CA Gersbach. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Exp. Cell Res. 300 (2004): 406-417.

Pages